by Martin Tolar, MD, PhD
Alzheon Founder, President & CEO

Alzheimer’s disease and the disabling loss of memory and independence that comes with it, affects more than 6.2 million people in the United States alone. Patients and physicians have been frustrated by the lack of treatment advances over the decades, but a new class of disease-modifying drugs has emerged and, in one case, retrospective research has spurred the development of a novel oral agent.

To learn more, we’ve invited Martin Tolar, MD, PhD, Alzheon Founder, President & CEO, to speak about the pharmaceutical landscape for Alzheimer’s disease and Alzheon’s drug in particular, ALZ-801 (valiltramiprosate).